[go: up one dir, main page]

MX2009008642A - Metodo para la identificacion de riesgo de desordenes de la tiroides. - Google Patents

Metodo para la identificacion de riesgo de desordenes de la tiroides.

Info

Publication number
MX2009008642A
MX2009008642A MX2009008642A MX2009008642A MX2009008642A MX 2009008642 A MX2009008642 A MX 2009008642A MX 2009008642 A MX2009008642 A MX 2009008642A MX 2009008642 A MX2009008642 A MX 2009008642A MX 2009008642 A MX2009008642 A MX 2009008642A
Authority
MX
Mexico
Prior art keywords
patient
thyroid
risk
developing
present
Prior art date
Application number
MX2009008642A
Other languages
English (en)
Inventor
David H Margolin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2009008642A publication Critical patent/MX2009008642A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para la identificación de un paciente que está en riesgo de desarrollar un desorden tiroideo que ocurre después de un tratamiento con un régimen que reduce linfocitos, el cual comprende el determinar si anticuerpos dirigidos contra la peroxidasa tiroidea o microsomas tiroideos están presentes en el paciente, en donde si los anticuerpos están presentes en el paciente entonces el paciente está en riesgo de desarrollar un desorden tiroideo. Una modalidad particular es un método para la identificación de un paciente con esclerosis múltiple que está en riesgo de desarrollar un desorden tiroideo que ocurre después de un tratamiento con un régimen que reduce células positivas a CD52, el cual comprende el determinar si anticuerpos dirigidos contra la peroxidasa tiroidea o microsomas tiroideos están presentes en el paciente, en donde si los anticuerpos están presentes en el paciente entonces el paciente está en riesgo de desarrollar un desorden tiroideo.
MX2009008642A 2007-02-16 2008-02-15 Metodo para la identificacion de riesgo de desordenes de la tiroides. MX2009008642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90173207P 2007-02-16 2007-02-16
PCT/US2008/002047 WO2008103292A1 (en) 2007-02-16 2008-02-15 Method of identifying risk for thyroid disorder

Publications (1)

Publication Number Publication Date
MX2009008642A true MX2009008642A (es) 2009-10-20

Family

ID=39434244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008642A MX2009008642A (es) 2007-02-16 2008-02-15 Metodo para la identificacion de riesgo de desordenes de la tiroides.

Country Status (21)

Country Link
US (3) US20100136587A1 (es)
EP (2) EP2538217A1 (es)
JP (2) JP5662684B2 (es)
CN (2) CN108303546B (es)
AU (1) AU2008219097B2 (es)
BR (1) BRPI0807601B8 (es)
CA (1) CA2678199A1 (es)
CY (1) CY1118663T1 (es)
DK (1) DK2130044T3 (es)
ES (1) ES2612558T3 (es)
HR (1) HRP20170121T1 (es)
HU (1) HUE031421T2 (es)
IL (2) IL200314A (es)
LT (1) LT2130044T (es)
MX (1) MX2009008642A (es)
PL (1) PL2130044T3 (es)
PT (1) PT2130044T (es)
RS (1) RS55636B1 (es)
RU (1) RU2013120485A (es)
SI (1) SI2130044T1 (es)
WO (1) WO2008103292A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
FR2934129B1 (fr) * 2008-07-24 2014-05-02 Oreal Procede de traitement cosmetique.
EP2335066B1 (en) * 2008-09-19 2016-12-28 University of Utah Research Foundation Methods for prediction of multiple sclerosis disease and therapy response
CN106257288A (zh) * 2016-08-15 2016-12-28 余洋 一种血清TPOAb IgG4水平检测方法
JP6992200B2 (ja) 2018-07-02 2022-02-03 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド 新規甲状腺ペルオキシダーゼ自己抗体イムノアッセイ
KR102469743B1 (ko) 2020-06-10 2022-11-22 주식회사 타이로스코프 약물 복용에 따른 갑상선 기능 모니터링 방법, 이를 수행하는 모니터링 서버 및 사용자 단말
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
WO2024158259A1 (ko) * 2023-01-27 2024-08-02 주식회사 타이로스코프 대상에 대한 갑상선기능이상증의 예측방법 및 시스템

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB2265713A (en) * 1992-05-16 1993-10-06 R S R Limited Assay for autoantibodies against thyroglobulin or thyroid peroxidase
DE19710211C2 (de) * 1997-03-12 1999-12-16 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Schilddrüsen-Autoantikörpern
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
JP2008523785A (ja) * 2004-10-12 2008-07-10 カーランテック，インコーポレーテッド 神経変性、自己免疫脱髄、および糖尿病のウイルス病原に対する動物モデル系
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)

Also Published As

Publication number Publication date
DK2130044T3 (en) 2017-02-06
RS55636B1 (sr) 2017-06-30
US20170307629A1 (en) 2017-10-26
JP5662684B2 (ja) 2015-02-04
ES2612558T3 (es) 2017-05-17
CN101657721A (zh) 2010-02-24
HUE031421T2 (hu) 2017-07-28
RU2013120485A (ru) 2014-11-20
JP2014149313A (ja) 2014-08-21
RU2009134313A (ru) 2011-03-27
PL2130044T3 (pl) 2017-04-28
CN108303546B (zh) 2023-01-03
JP6058585B2 (ja) 2017-01-11
CY1118663T1 (el) 2017-07-12
CA2678199A1 (en) 2008-08-28
PT2130044T (pt) 2017-02-03
HRP20170121T1 (hr) 2017-03-24
US20100136587A1 (en) 2010-06-03
AU2008219097A1 (en) 2008-08-28
US20130095507A1 (en) 2013-04-18
US10648986B2 (en) 2020-05-12
US9664688B2 (en) 2017-05-30
BRPI0807601B1 (pt) 2021-02-23
SI2130044T1 (sl) 2017-03-31
EP2130044A1 (en) 2009-12-09
CN101657721B (zh) 2018-02-23
IL200314A (en) 2015-11-30
HK1257419A1 (zh) 2019-10-18
BRPI0807601B8 (pt) 2021-07-27
WO2008103292A1 (en) 2008-08-28
JP2010519512A (ja) 2010-06-03
EP2130044B1 (en) 2016-10-26
BRPI0807601A2 (pt) 2014-05-06
AU2008219097B2 (en) 2011-06-23
IL242391A (en) 2017-09-28
IL200314A0 (en) 2010-04-29
CN108303546A (zh) 2018-07-20
EP2538217A1 (en) 2012-12-26
LT2130044T (lt) 2017-02-10

Similar Documents

Publication Publication Date Title
MX2009008642A (es) Metodo para la identificacion de riesgo de desordenes de la tiroides.
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
EP2589011A4 (en) SYSTEM AND METHOD FOR MANAGING RECIPES ON SITE FOR HEALTH EQUIPMENT
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
MX2009013410A (es) Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
EP2350829A4 (en) METHOD AND SYSTEM FOR DETERMINING THE USE OF COMPUTER RESOURCES IN SERVICE COMPUTING
EP2163092A4 (en) VIRTUAL INTERACTIVE PRESENCE SYSTEMS AND METHODS
WO2012166899A3 (en) Biomarkers for predicting and assessing responsiveness to lenvatinib compounds
PH12013500826A1 (en) Means and methods for treating dlbcl
TW200710675A (en) Methods and apparatus for resource management in a logically partitioned processing environment
ES2364314T8 (es) Detección y predicción de preeclampsia.
GB0711327D0 (en) Diagnostic method
GB2505609A (en) Combining key control information in common cryptographic architecture services
EP2569445A4 (en) SCREENING ASSAYS BASED ON MAG AND / OR ABHDB FOR THE SELECTION OF INSULINATION-PROMOTING MEANS
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
MX342907B (es) El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
BRPI1009573A2 (pt) método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente.
WO2014100602A8 (en) Treatment of egf-receptor dependent pathologies
MY170810A (en) Method, device, and storage medium for setting up application runtime environment
UA104741C2 (uk) Моноклональні антитіла проти феропортину 1 та варіанти їх застосування
CL2011000324A1 (es) Receptaculo para el manejo de peces contagiosos o muertos que comprende un casco con una cubierta generalmente cerrada, una entrada para recibir dichos peces en un molino de pescado; y metodo para el manejo de peces contagiosos o muertos.
EP2110740A4 (en) CALCULATING PROCESSOR, INFORMATION PROCESSOR AND CALCULATION METHOD
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment
MX2014011045A (es) Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib.

Legal Events

Date Code Title Description
FG Grant or registration